Novacyt (LON:NCYT) Shares Up 6% – Still a Buy?

Novacyt S.A. (LON:NCYT) shares shot up 6% during trading on Tuesday. The company traded as high as GBX 46.70 and last traded at GBX 42.40. 751,683 shares were traded during trading, an increase of 326% from the average daily volume of 176,544 shares. The stock had previously closed at GBX 40.

Novacyt Stock Performance

The company has a market capitalization of £30.74 million, a P/E ratio of -1.37 and a beta of 1.11. The firm has a 50 day moving average price of GBX 41.89 and a two-hundred day moving average price of GBX 39.26. The company has a debt-to-equity ratio of 54.74, a quick ratio of 4.46 and a current ratio of 3.14.

Novacyt (LON:NCYT) last issued its earnings results on Wednesday, September 30th. The company reported GBX (8) EPS for the quarter. Novacyt had a negative net margin of 91.67% and a negative return on equity of 126.76%.

Novacyt Company Profile

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.